/ Pre-IPO Risk Index / Verily Life Sciences

Verily Life Sciences

Healthcare AI · Pre-IPO · ~$22B (last formal — Alphabet subsidiary)
C

Mixed (C) — Round Z Pre-IPO Risk Grade

Verily operates as an Alphabet subsidiary focused on healthcare data, devices, and precision-health research. Multiple business-strategy pivots 2023-2024; layoffs Q1 2023 and Q3 2024. Alphabet subsidiary status produces unusual structural ownership for secondary investors.

58
Composite / 100
/ Subscore Breakdown · 5 Dimensions

Where this grade comes from.

Governance Risk
C
Valuation Methodology
C
Secondary Liquidity
D+
Financial Disclosure
C-
Exit Probability
C-
/ Public-Record Events

Key risk events & disclosures.

  • Multiple business-strategy pivots 2023-2024
  • Layoffs Q1 2023 (~15% of workforce) and Q3 2024
  • Alphabet subsidiary status; minority third-party investment 2022
  • Workbench platform expansion 2024

/ Best for

Limited recommendation outside Alphabet shareholders. Third-party secondary investors face structural minority-protection limitations.

/ Watch out for

Alphabet subsidiary status means exit optionality depends on parent-company decisions.